• Global Clinical Innovation -
  Co-developer of the Mild Behavioural Impairment (MBI) Checklist, the world’s only MBI-specific assessment tool, translated into 20+ languages and utilised globally in research, clinical practice, and industry trials.

 

• Standard-Setting Diagnostics –
  Co-developer of the new apathy diagnostic criteria and lead author of the internationally recognised roadmap to address apathy as a treatment target.

 

• Global Science Governance –
  Served as a Scientific Program Committee member for the Alzheimer’s Association International Conference (AAIC, 2021-2024), shaping the agenda for the world’s largest dementia research forum.

 

• Longitudinal Research Leadership – 
  Member of the Governance Committee (2018-2026) and Lead of the Neuropsychiatric Symptoms sub-study of the UNSW/ANU PATH Through Life Study, a landmark 20-year population-based project.

 

• Global Thought Leadership –
  A prolific record of peer-reviewed scientific publications and international presentations, bringing world-class intellectual rigour to every advisory engagement.

 

• Elite Research Pedigree –
  Backed by Dr Mortby’s 15+ years of research experience at UNSW, NeuRA and ANU, providing a level of scientific authority that is unmatched in the consulting space.

• Global Strategic Recognition -
  Invited expert consultant for global industry leaders like Cerevel Therapeutics, and national bodies including Dementia Training Australia and the ACT Government.

 

• Symposium Leadership –
  Chair and Lead Organiser of the inaugural Australasian Neuropsychiatric Syndromes Symposium (ANSS 2025), a premier 3-day international event in Sydney.

 

• Applied Impact –
  Lead of the BPSDPLUS Program, a person-centred training and care framework for aged care staff designed to support residents with neuropsychiatric symptoms.

 

• Success in Grant Acquisition –

Proven success in developing fundable narratives and securing high-value research grants within the national and international ageing and dementia sector.

 

• Global Research Network –  
  Active engagement and leadership within international bodies including the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) and the International Society for CNS Clinical Trials and Methodology (ISCTM), ensuring strategies are informed by global clinical and scientific evidence.

 

• Strategic Relationship Management –

Acting as a trusted intermediary to manage complex, cross-sector partnerships between industry leaders, health care providers, and academic institutions.